Unknown

Dataset Information

0

Phenprocoumon Dose Requirements, Dose Stability and Time in Therapeutic Range in Elderly Patients With CYP2C9 and VKORC1 Polymorphisms.


ABSTRACT: Background:Dose requirements of vitamin K antagonists are associated with CYP2C9 and VKORC1, but, compared to warfarin, less data is available about phenprocoumon. Furthermore, the effects on dose stability and anticoagulation quality are still unclear. Methods:Aim was to scrutinize phenprocoumon dose requirements, dose stability and anticoagulation quality in association to CYP2C9 and VKORC1 in a natural cohort of elderly primary care patients. As a subgroup within the IDrug study, phenprocoumon treated patients with at least two INR values within three months before enrollment (n = 209) were analyzed concerning average weekly dose, standard deviation of weekly dose (intra-subject variability), constant dose (yes/no), average INR and TTR grouped by CYP2C9 and VKORC1 (and combinations). Results:Average weekly dose per patient was 14.4 ± 5.3 mg, 11.9 ± 4.0 mg and 11.2 ± 4.3 mg in CYP2C9 wildtypes, *2 and *3 carriers (p < .0001) and 16.0 ± 4.2 mg, 13.3 ± 5.1 mg and 8.0 ± 2.7 mg per week in VKORC1 CC, CT and TT genotypes, respectively (p < .0001). Significant differences concerning intra-subject variability were detected among all groups (p < .0001) with the smallest variability in CYP2C9*3 carriers. TTR medians were 75.4%, 79.4% and 100% in wildtypes, *2 and *3 carriers, respectively (p = 0.0464). The proportion of patients with perfect control was highest among *3 carriers, but this result was not significant (p = 0.0713). Discussion:Our analyses support the results of previous investigations regarding genotype-associated dose requirements and raise the hypothesis that dose stability and anticoagulation quality may be increased in CYP2C9*3 carriers. However, our data should be treated cautiously due to the small sample size. Clinical Trial Registration:German Clinical Trials Register, identifier DRKS00006256.

SUBMITTER: Schneider KL 

PROVIDER: S-EPMC6997201 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

Phenprocoumon Dose Requirements, Dose Stability and Time in Therapeutic Range in Elderly Patients With <i>CYP2C9</i> and <i>VKORC1</i> Polymorphisms.

Schneider Katharina Luise KL   Kunst Melanie M   Leuchs Ann-Kristin AK   Böhme Miriam M   Weckbecker Klaus K   Kastenmüller Kathrin K   Bleckwenn Markus M   Holdenrieder Stefan S   Coch Christoph C   Hartmann Gunther G   Stingl Julia Carolin JC  

Frontiers in pharmacology 20200128


<h4>Background</h4>Dose requirements of vitamin K antagonists are associated with <i>CYP2C9</i> and <i>VKORC1</i>, but, compared to warfarin, less data is available about phenprocoumon. Furthermore, the effects on dose stability and anticoagulation quality are still unclear.<h4>Methods</h4>Aim was to scrutinize phenprocoumon dose requirements, dose stability and anticoagulation quality in association to <i>CYP2C9</i> and <i>VKORC1</i> in a natural cohort of elderly primary care patients. As a su  ...[more]

Similar Datasets

| S-EPMC6684853 | biostudies-literature
| S-EPMC3718044 | biostudies-literature
| S-EPMC4453805 | biostudies-literature
| S-EPMC6380714 | biostudies-literature
| S-EPMC4393720 | biostudies-literature
| S-EPMC6429271 | biostudies-literature
| S-EPMC5207541 | biostudies-literature
| S-EPMC2887839 | biostudies-literature
| S-EPMC2440373 | biostudies-literature
| S-EPMC3712827 | biostudies-literature